364 related articles for article (PubMed ID: 32429721)
1. Development and Evaluation of Novel Aptamers Specific for Human PD1 Using Hybrid Systematic Evolution of Ligands by Exponential Enrichment Approach.
Khedri M; Abnous K; Rafatpanah H; Nabavinia MS; Taghdisi SM; Ramezani M
Immunol Invest; 2020 Jul; 49(5):535-554. PubMed ID: 32429721
[TBL] [Abstract][Full Text] [Related]
2. A PD-L1 Aptamer Selected by Loss-Gain Cell-SELEX Conjugated with Paclitaxel for Treating Triple-Negative Breast Cancer.
Wu X; Li F; Li Y; Yu Y; Liang C; Zhang B; Zhao C; Lu A; Zhang G
Med Sci Monit; 2020 Jun; 26():e925583. PubMed ID: 32574155
[TBL] [Abstract][Full Text] [Related]
3. Screening and characterization of aptamers for recombinant human programmed death-1 and recombinant extracellular domain of human programmed death ligand-1.
Li ZF; Chen C; Zeng JY; Wang S; Han SQ; Zhang YQ; Qiu DD; Guo HX
Eur Rev Med Pharmacol Sci; 2021 Jun; 25(11):3997-4004. PubMed ID: 34156677
[TBL] [Abstract][Full Text] [Related]
4. Aptamers Targeting the PD-1/PD-L1 Axis: A Perspective.
Bertrand P
J Med Chem; 2023 Aug; 66(16):10878-10888. PubMed ID: 37561598
[TBL] [Abstract][Full Text] [Related]
5. SELEX methods on the road to protein targeting with nucleic acid aptamers.
Bayat P; Nosrati R; Alibolandi M; Rafatpanah H; Abnous K; Khedri M; Ramezani M
Biochimie; 2018 Nov; 154():132-155. PubMed ID: 30193856
[TBL] [Abstract][Full Text] [Related]
6. An optimized protocol for the in vitro generation and functional analysis of human PD1/PD-L1 signal.
Khedri M; Abnous K; Rafatpanah H; Ramezani M
J Recept Signal Transduct Res; 2018 Feb; 38(1):31-36. PubMed ID: 29252078
[TBL] [Abstract][Full Text] [Related]
7. Agonist redirected checkpoint, PD1-Fc-OX40L, for cancer immunotherapy.
Fromm G; de Silva S; Johannes K; Patel A; Hornblower JC; Schreiber TH
J Immunother Cancer; 2018 Dec; 6(1):149. PubMed ID: 30563566
[TBL] [Abstract][Full Text] [Related]
8. Development of Cell-Specific Aptamers: Recent Advances and Insight into the Selection Procedures.
Rahimizadeh K; AlShamaileh H; Fratini M; Chakravarthy M; Stephen M; Shigdar S; Veedu RN
Molecules; 2017 Nov; 22(12):. PubMed ID: 29186905
[TBL] [Abstract][Full Text] [Related]
9. Anti-PD-L1 DNA aptamer antagonizes the interaction of PD-1/PD-L1 with antitumor effect.
Gao T; Mao Z; Li W; Pei R
J Mater Chem B; 2021 Jan; 9(3):746-756. PubMed ID: 33319876
[TBL] [Abstract][Full Text] [Related]
10. An improved SELEX technique for selection of DNA aptamers binding to M-type 11 of Streptococcus pyogenes.
Hamula CL; Peng H; Wang Z; Tyrrell GJ; Li XF; Le XC
Methods; 2016 Mar; 97():51-7. PubMed ID: 26678795
[TBL] [Abstract][Full Text] [Related]
11. PD1 (CD279) and PD-L1 (CD274, B7H1) expression in primary central nervous system lymphomas (PCNSL).
Berghoff AS; Ricken G; Widhalm G; Rajky O; Hainfellner JA; Birner P; Raderer M; Preusser M
Clin Neuropathol; 2014; 33(1):42-9. PubMed ID: 24359606
[TBL] [Abstract][Full Text] [Related]
12. PD1-CD28 Fusion Protein Enables CD4+ T Cell Help for Adoptive T Cell Therapy in Models of Pancreatic Cancer and Non-hodgkin Lymphoma.
Rataj F; Kraus FBT; Chaloupka M; Grassmann S; Heise C; Cadilha BL; Duewell P; Endres S; Kobold S
Front Immunol; 2018; 9():1955. PubMed ID: 30214445
[No Abstract] [Full Text] [Related]
13. Discovery of Aptamers Against Cell Surface Markers Using Ligand-Guided Selection.
Williams N; Patel R; Mallikaratchy P
Methods Mol Biol; 2023; 2570():13-38. PubMed ID: 36156771
[TBL] [Abstract][Full Text] [Related]
14. A combinatorial systematic evolution of ligands by exponential enrichment method for selection of aptamer against protein targets.
Mondal B; Ramlal S; Lavu PS; Murali HS; Batra HV
Appl Microbiol Biotechnol; 2015 Nov; 99(22):9791-803. PubMed ID: 26293334
[TBL] [Abstract][Full Text] [Related]
15. The Development and Characterisation of ssDNA Aptamers via a Modified Cell-SELEX Methodology for the Detection of Human Red Blood Cells.
Costanzo H; Gooch J; Tungsirisurp S; Frascione N
Int J Mol Sci; 2024 Feb; 25(3):. PubMed ID: 38339091
[TBL] [Abstract][Full Text] [Related]
16. In vivo positron emission tomography imaging for PD-L1 expression in cancer using aptamer.
Choi YJ; Park JY; Cho YL; Chae JR; Cho H; Kang WJ
Biochem Biophys Res Commun; 2022 Sep; 620():105-112. PubMed ID: 35780578
[TBL] [Abstract][Full Text] [Related]
17. A highly specific aptamer probe targeting PD-L1 in tumor tissue sections: Mutation favors specificity.
Ren X; Li J; Wu X; Zhao J; Yang Q; Lou X
Anal Chim Acta; 2021 Nov; 1185():339066. PubMed ID: 34711320
[TBL] [Abstract][Full Text] [Related]
18. Development of Cell-SELEX Technology and Its Application in Cancer Diagnosis and Therapy.
Chen M; Yu Y; Jiang F; Zhou J; Li Y; Liang C; Dang L; Lu A; Zhang G
Int J Mol Sci; 2016 Dec; 17(12):. PubMed ID: 27973403
[TBL] [Abstract][Full Text] [Related]
19. Comparison of whole-cell SELEX methods for the identification of Staphylococcus aureus-specific DNA aptamers.
Moon J; Kim G; Park SB; Lim J; Mo C
Sensors (Basel); 2015 Apr; 15(4):8884-97. PubMed ID: 25884791
[TBL] [Abstract][Full Text] [Related]
20. Tumor PD-L1 co-stimulates primary human CD8(+) cytotoxic T cells modified to express a PD1:CD28 chimeric receptor.
Prosser ME; Brown CE; Shami AF; Forman SJ; Jensen MC
Mol Immunol; 2012 Jul; 51(3-4):263-72. PubMed ID: 22503210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
